Inhibition of prostate cancer DU145 cell growth with small interfering RNA targeting the SATB1 gene

Abstract

Abstract. Prostate cancer is a common visceral cancer of men worldwide. It is important to develop a more effective treatment for prostate cancer to overcome the treatment resistance that occurs with recurrence. RNA interference has been demonstrated to be a powerful tool for gene knockdown and has potential as a cancer treatment. It has been previously demonstrated that staining of special AT-rich sequence-binding protein 1 (SATB1) was stronger in prostatic carcinoma with metastasis compared with prostatic carcinoma without metastasis. In the present study, SATB1 small interfering (si)RNA was transfected into prostate cancer DU145 cells and normal human lung fibroblast cells, and cell proliferation was investigated using a Cell Counting kit-8. Three siRNA were transfected into cells using siPORT Lipid Transfection agent, and blank control and negative control groups were established. The cells were harvested and SATB1 mRNA and protein expression was determined by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. DU145 cell adhesion, migration and invasion capabilities were determined using cell adhesion, Transwell and Transwell with Matrigel assays, respectively. Silencing SATB1 significantly inhibited DU145 cell growth, adhesion, migration and invasive capability in vitro, indicating that a SATB1-targeting siRNA was successfully engineered.The results of the present study suggest that SATB1 siRNA may be a potential agent for treating human prostate cancer.

Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution

“…We found that antibody-free nanocarrier and antibody-functionalized nanocarrier triggered very week response of a small number of genes in vitro. Most of the genes deregulated by NaA-silane-PEG and NaA-silane-PEG-D2B encode proteins involved in both stimulation and suppression of pro-inflammatory responses [35][36][37][38][39]. Simultaneous deregulation of genes encoding proteins that are key to both pro-inflammatory and antiinflammatory responses in the same cell line does not allow a definitive statement about the immunotoxicity of these carriers.…”

Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer

“…Thus, targeting SATB1 is of importance in PCa therapy. It was shown that downregulation of SATB1 using siRNA can pave the way for a reduction in growth, proliferation, and metastasis of PCa cells [ 77 ]. The siRNA-mediated Bcl-xL downregulation potentiates the inhibitory effect on the malignancy and growth of PCa cells [ 78 ].…”

Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results

“…Based on literature data, toxicogenomics serves as a promising tool to explore nanocarrier-associated immunotoxicity and related processes such as hypersensitivity, immunogenicity, autoimmunity, and immunosuppression [ 56 , 106 , 107 ]. In contrast to the above-mentioned information, Lankoff et al [ 56 ] could not draw a conclusion regarding the in vitro immunotoxic effects of NaA nanozeolite nanocarriers (NaA-silane-PEG and NaA-silane-PEG-D2B) because they experienced the deregulation of both the pro- and anti-inflammatory genes induced by these nanocarriers [ 56 , 108 , 109 ]. For this reason, relevant studies are required to uncover those aspects of nanoparticle-related toxicity that are poorly understood yet.…”